You are here
Why People With Diabetes Can’t Buy Generic Insulin
A generic version of insulin, the lifesaving diabetes drug used by 6 million people in the U.S., has never been available in this country because drug companies have made incremental improvements that kept insulin under patent from 1923 to 2014. As a result, say two Johns Hopkins researchers, many people who need insulin to control their diabetes can’t afford it, and some end up hospitalized with life-threatening complications, such as kidney failure and diabetic coma.
In a study published March 19 in the New England Journal of Medicine, authors Jeremy Greene, MD, PhD, and Kevin Riggs, MD, MPH, describe the history of insulin as an example of “evergreening,” in which pharmaceutical companies make a series of improvements to important medications that extend their patents for many decades. This keeps older versions off the generic market, the authors say, because generic manufacturers have less incentive to make a version of insulin that doctors perceive as obsolete. Newer versions are somewhat better for patients who can afford them, say the authors, but those who can’t suffer painful, costly complications.
“We see generic drugs as a rare success story, providing better quality at a cheaper price,” says Greene. “And we see the progression from patented drug to generic drug as almost automatic. But the history of insulin highlights the limits of generic competition as a framework for protecting the public health.”
More than 20 million Americans have diabetes. The disease can often be managed without drugs or with oral medications, but some patients need daily insulin injections. The treatment can cost from $120 to $400 per month without prescription drug insurance.
“Insulin is an inconvenient medicine even for people who can afford it,” says Riggs. “When people can’t afford it, they often stop taking it altogether.”
Patients with diabetes who are not taking prescribed insulin come to Riggs and Greene’s Baltimore-area clinics complaining of blurred vision, weight loss, and intolerable thirst — symptoms of uncontrolled diabetes, which can lead to blindness, kidney failure, gangrene, and the loss of limbs.
The two doctors decided to find out why no one makes generic insulin. A University of Toronto medical team discovered insulin in 1921, and in 1923, the university, which held the first patent, gave drug companies the right to manufacture it and to patent any improvements. In the 1930s and 1940s, pharmaceutical companies developed long-acting forms that allowed most patients to take a single daily injection. In the 1970s and 1980s, manufacturers improved the purity of cow- and pig-extracted insulin. Since then, several companies have developed synthetic analogs.
Biotech insulin is now the standard in the U.S., the authors say. Patents on the first synthetic insulin expired in 2014, but these newer forms are harder to copy, so the unpatented versions will go through a lengthy FDA approval process and will cost more to make. When these insulins come on the market, they may cost only 20% to 40% less than the patented versions, Riggs and Greene write.
Source: Johns Hopkins Medicine; March 18, 2015.